Information Provided By:
Fly News Breaks for March 11, 2015
CLDX
Mar 11, 2015 | 07:59 EDT
Cantor raised its price target on Celldex after the company received Breakthrough Designation for its rindopepimut drug from the FDA. The firm thinks that the designation increases the chances that the drug will be commercialized as a treatment for relapsed Avastin-naive patients on an accelerated basis. The firm is upbeat on the company's outlook and keeps a Buy rating on the shares.
News For CLDX From the Last 2 Days
There are no results for your query CLDX
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.